Kit, system and method of treating myeloma patients
First Claim
1. A method of treating a patient having myeloma, the method comprising the steps of:
- treating the myeloma patient before development of acute renal failure in the patient by extracting and separating the patient'"'"'s plasma from the patient'"'"'s blood;
removing elevated levels of either lambda or kappa free light chains or both from the patient'"'"'s plasma by contacting the extracted and separated plasma with a hydrophobic resin, an ion exchange resin, a silica resin or a combination thereof to obtain purified plasma; and
re-infusing the purified plasma into the patient.
2 Assignments
0 Petitions
Accused Products
Abstract
Circulating free lambda and kappa free light chains in blood play a role in the pathogenesis of acute renal failure due to myeloma. Coupled plasma filtration and adsorption allows separation of plasma from blood and treatment of the plasma through a cartridge containing a sorbent or resin material, such as hydrophobic divinylbenzene styrenic resins having an average bead diameter of 75 microns, an average pore diameter of 30 nm, and a surface area of 700 m2/g. Lambda and kappa free light chain concentrations progressively decrease during coupled plasma filtration and adsorption treatment resulting in significant reductions by the end of the treatment.
-
Citations
13 Claims
-
1. A method of treating a patient having myeloma, the method comprising the steps of:
-
treating the myeloma patient before development of acute renal failure in the patient by extracting and separating the patient'"'"'s plasma from the patient'"'"'s blood; removing elevated levels of either lambda or kappa free light chains or both from the patient'"'"'s plasma by contacting the extracted and separated plasma with a hydrophobic resin, an ion exchange resin, a silica resin or a combination thereof to obtain purified plasma; and re-infusing the purified plasma into the patient. - View Dependent Claims (2, 3, 4, 5, 6)
-
-
7. A method of preventing acute renal failure in a patient diagnosed with myeloma, the method comprising the step of purifying the plasma of the myeloma patient before development of acute renal failure in the patient after extracting and separating the patient'"'"'s plasma from the patient'"'"'s blood by contacting the extracted and separated plasma with a hydrophobic resin, an ion exchange resin, a silica resin, or a combination thereof to simultaneously reduce levels of either lambda or kappa free light chains or both;
- and reduce the levels of inflammatory mediators or uremic toxins.
- View Dependent Claims (8)
- 9. A method of using a hydrophobic resin, an ion exchange resin, a silica resin or a combination thereof to treat a patient having myeloma, wherein the hydrophobic resin, ion exchange resin, silica resin or combination thereof removes elevated levels of either lambda or kappa free light chains or both from plasma of the patient before development of acute renal failure in the myeloma patient by contacting the patient'"'"'s plasma with the hydrophobic resin, ion exchange resin, silica resin or combinations thereof after the patient'"'"'s plasma has been extracted and separated from the patient'"'"'s blood.
Specification